This is a working overview of Somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Groth examined the change in symmetry of a crystal as a result of the replacement of a hydrogen atom by another univalent atom or radical. Morphotropy is also referred to as isogonism in which each vertex is surrounded by the same kinds of face in the same or reverse order, and with the same angles between corresponding faces. In 1897 Wilhelm Ostwald introduced Ostwald's rule, to describe the formation of polymorphs. The rule states that usually the less stable polymorph crystallizes first. Ostwald's rule is not a universal law but a common tendency observed in nature.
By 1951, Alec Todd and collaborators at the University of Cambridge had determined by biochemical methods how the backbone of DNA is structured via the successive linking of carbon atoms 3 and 5 of the sugar to phosphates. This would help to corroborate Watson and Crick's later X-ray structural work. Todd would later be awarded the 1957 Nobel Prize in Chemistry for this and other discoveries related to DNA. Late in 1951, Francis Crick started working with James Watson at the Cavendish Laboratory within the University of Cambridge. DNA's role in heredity was confirmed in 1952 when Alfred Hershey and Martha Chase in the Hershey–Chase experiment showed that DNA is the genetic material of the enterobacteria phage T2.
1968–1973 – 1.0 L (985 cc) PB I4, 50 hp (37 kW; 51 PS) / 56 lb⋅ft (76 N⋅m) 1968–1970 – 1.2 L (1169 cc) TB I4, 58 hp (43 kW; 59 PS) / 69 lb⋅ft (94 N⋅m) 1970–1973 – 1.3 L (1272 cc) TC I4, 2-barrel, 69 hp (51 kW; 70 PS) / 67 lb⋅ft (91 N⋅m) The pickup received the BPB55, BTA55/65, or FA2T55/65/66 model codes respectively when fitted with the OHV 1.0 or 1.2, or the OHC 1.3. FA2T55 was a short bed with 500 kg (1,100 lb) max load, 65 was a long bed with the same capacity, while the 66 upped that to 600 kg (1,300 lb). All three models were available as either Standard or Deluxe. The 1000 Van (Japanese terminology for the station wagon, which was intended for commercial use there) received either BPCV or BPBV chassis codes, signifying three- or five-door versions. The Familia Presto Van, with OHC engines, received chassis numbers MP3xV/SP3xV for the 1000 (3-door/5-door) and MT2xV/ST2xV for the 1200. The five-door Van range was gradually expanded downwards as the three-door models dropped in popularity. The Familia Presto Van continued largely unchanged until the summer of 1978, aside from the 1.3 losing two horsepower along the way.
=== Kh-Kn === Har Gobind Khorana (1922–2011). Indian-American biochemist at the University of Wisconsin, who participated in elucidating the genetic code. Nobel Prize for Physiology or Medicine (1968). Member Natl. Acad. Sci. USA. Ann Kimble-Hill (21st century). American biochemist studying structure-function relationships of membrane proteins and lipids Charles Glen King (1896–1988). American biochemist at the University of Pittsburgh. He isolated vitamin C, and was a pioneer in the field of nutrition research. Judith Klinman (b. 1941). American chemist, biochemist, and molecular biologist at UC Berkeley, known for her work on enzyme catalysis. Member Natl. Acad. Sci. USA. Aaron Klug FRS (President) (1926–2018). Lithuanian/South African/British structural biologist at Cambridge University. Nobel Prize in Chemistry (1982). Foreign associate Natl. Acad. Sci. USA. Franz Knoop (1875–1946). German biochemist at the University of Tübingen known for the discovery of β-oxidation. Jeremy Randall Knowles FRS (1935–2008). British and American biochemist at Oxford and Harvard, known for research on enzyme mechanisms. Foreign Associate Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
==== Psychotherapy ==== Psychotherapy for individuals with AN is challenging as they may value being thin and may seek to maintain control and resist change. Initially, developing a desire to change is fundamental. There is no strong evidence to suggest one type of psychotherapy over another for treating anorexia nervosa in adults or adolescents.
=== Caucus leadership === On February 1, 2006, Larson was elected vice chair of the House Democratic Caucus to succeed Jim Clyburn, who was elevated to chair. After the caucus won control of the House in the 2006 elections, Clyburn was elevated to majority whip. However, Larson opted not to run for chair, and Clyburn was succeeded by Rahm Emanuel. After the 2008 elections, Emanuel became White House Chief of Staff and Larson was elected caucus chair. He served as chair for two terms before leaving the party leadership.
The batch-to-batch variations arising from the needs during the mentioned methodology can be overcome by utilizing technical components for mixing and growth as well as transport and temperature adjustments. For the production of CdSe based semiconductor nanoparticles this method has been investigated and tuned to production amounts of kilograms per month. Since the use of technical components allows for easy interchange in regards of maximum throughput and size, it can be further enhanced to tens or even hundreds of kilograms. In 2011 a consortium of U.S. and Dutch companies reported a milestone in high-volume quantum dot manufacturing by applying the traditional high temperature dual injection method to a flow system. On 23 January 2013 Dow entered into an exclusive licensing agreement with UK-based Nanoco for the use of their low-temperature molecular seeding method for bulk manufacture of cadmium-free quantum dots for electronic displays, and on 24 September 2014 Dow commenced work on the production facility in South Korea capable of producing sufficient quantum dots for "millions of cadmium-free televisions and other devices, such as tablets". Mass production was due to commence in mid-2015. On 24 March 2015, Dow announced a partnership deal with LG Electronics to develop the use of cadmium free quantum dots in displays.
Carlos do Carmo said he did not know the reason why Dias had said: "If you want Rui Pedro close the borders". Hernâni Carvalho ended the interview by telling Carlos do Carmo:"I would like to leave this enigma: by curiosity, by paradox or by pure coincidence, two days before Rui Pedro disappeared (...) an eleven year old boy disappeared (...) no one found out anything about him either"Júlia Pinheiro questioned Francisco Moita Flores in 2011 about the police not having connected the fact that Afonso Dias had ties to Holland. Moita Flores agreed that it was a path that should have been followed. It was also questioned the fact Dias' financial life was not investigated and that during the reconstitution, the camera stopped recording the event, without it being noticed. Manuel Mendonça said that the police "joked around" with the case for three or four years, without recording things, gathering samples or DNA tests, always thinking that Mendonça would come back because he was playing or had run from home.
==== Amyloid beta (Aβ) ==== Alzheimer's disease has been identified as a protein misfolding disease, a proteopathy, caused by the accumulation of abnormally folded Aβ protein into amyloid plaques, and tau protein into neurofibrillary tangles in the brain. Plaques are made up of small peptides, 39–43 amino acids in length, called Aβ. Aβ is a fragment derived from the larger Aβ precursor protein (APP), a transmembrane protein that penetrates the cell's membrane. APP is critical to neuronal growth, survival, and post-injury repair. In Alzheimer's disease, the enzymes gamma secretase and beta secretase act together in a proteolytic process that divides APP into smaller fragments. One of these fragments is Aβ, which misfolds and self-assembles into fibrils; these fibrils form clumps that deposit outside neurons in dense formations known as Aβ plaques. Excitatory neurons are known to be major producers of Aβ that contribute to extracellular plaque deposition.
Sources: en.wikipedia.org
Throat culture Anti-DNAse B titre (peaks at 8–12 weeks after infection) Anti-streptolysin O titre (peaks at 3–5 weeks) None of these tests are 100% reliable, particularly when the infection was some months previously. Further testing is directed more towards alternative diagnoses and other manifestations of rheumatic fever:
Proenkephalin (PENK), formerly known as proenkephalin A (since proenkephalin B was renamed prodynorphin), is an endogenous opioid polypeptide hormone which, via proteolyic cleavage, produces the enkephalin peptides met-enkephalin, and to a lesser extent, leu-enkephalin. Upon cleavage, each proenkephalin peptide results in the generation of four copies of Met-enkephalin, two extended copies of met-enkephalin, and one copy of leu-enkephalin. Contrarily, Leu-enkephalin is predominantly synthesized from prodynorphin, which produces three copies of it per cleavage, and no copies of Met-enkephalin. Other endogenous opioid peptides produced by proenkephalin include adrenorphin, amidorphin, BAM-18, BAM-20P, BAM-22P, peptide B, peptide E, and peptide F. The following table lists the peptides that are derived from cleavage of the proenkephalin protein.
== Medical uses == Metandienone was formerly approved and marketed as a form of androgen replacement therapy for the treatment of hypogonadism in men, but has since been discontinued and withdrawn in most countries, including in the United States. It was given at a dosage of 5 to 10 mg/day in men and 2.5 mg/day in women.
== Structure == IDH1 is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3, and encoded by one of five isocitrate dehydrogenase genes, which are IDH1, IDH2, IDH3A, IDH3B, and IDH3G. IDH1 forms an asymmetric homodimer in the cytoplasm and carries out its function through two hydrophilic active sites formed by both protein subunits. Each subunit or monomer is composed of three domains: a large domain (residues 1–103 and 286–414), a small domain (residues 104–136 and 186–285), and a clasp domain (residues 137 to 185). The large domain contains a Rossmann fold, while the small domain forms an α/β sandwich structure, and the clasp domain folds as two stacked double-stranded anti-parallel β-sheets. A β-sheet joins the large and small domains and is flanked by two clefts on opposite sides. The deep cleft, also known as the active site, is formed by the large and small domains of one subunit and a small domain of the other subunit. This active site includes the NADP-binding site and the isocitrate-metal ion-binding site. The shallow cleft, also referred to as the back cleft, is formed by both domains of one subunit and participates in the conformational changes of homodimeric IDH1. Finally, the clasp domains of both subunits intertwine to form a double layer of four-stranded anti-parallel β-sheets linking together the two subunits and the two active sites. Furthermore, conformational changes to the subunits and a conserved structure at the active site affect the activity of the enzyme.
=== Photography series === 1996–1998: Homonymes (portraits of ordinary people with the same names as famous people) 1998: Reconstitutions - Rêves Reconstitués 2000–2002: Angoisse, Philéas Fogg (photographs taken around the city of Angoisse, whose name in French means "anguish") 2001–2002: Reconstitutions - Actualités (staged and anonymized photos playing on the stereotypes of press photography) 2002: Reconstitutions - Pornographie (clothed models in pornographic positions) 2003: Reconstitutions - Rugby (models in street clothing posed in rugby positions sans ball) 2003: Reconstitutions - Quotidien (newspaper or magazine photographs, restaged with actors who are anonymized and in everyday clothing against a black background)
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.